A bald patch can look like an absence. Under the skin, the follicle may still be waiting. That is one of the quirks of alopecia areata, and it helps explain the interest in Rinvoq for alopecia areata.
Rinvoq is the brand name for upadacitinib, an oral JAK inhibitor already used for several immune-mediated conditions. In 2026, the European indication expanded to severe alopecia areata in adults and adolescents 12 years of age and older. The tablet is taken once a day; visible regrowth, if it comes, moves on a much slower clock.
What is alopecia areata actually doing?
Alopecia areata is an autoimmune form of hair loss. The immune system turns against growing follicles and interrupts their normal cycle. One smooth patch may appear first. In more extensive disease, the scalp, eyebrows, eyelashes, or body hair can all be involved.
The important part sits underneath. Alopecia areata is usually nonscarring, so the follicle is not simply erased from the skin. A peer-reviewed review of its pathogenesis describes the loss of normal immune protection around the follicle and the inflammatory signals that follow.
That is also why active alopecia areata is different from permanent pattern baldness. A hair transplant in Turkey redistributes healthy donor follicles; it does not switch off an autoimmune attack.
Why would Rinvoq affect hair?
JAK proteins help carry messages involved in inflammation and immune activity. Rainbow (upadacitinib) blocks part of that signaling pathway. In alopecia areata, the goal is to reduce the signals that help sustain the attack around the follicle.
Hair comes later in the chain. Rinvoq does not coat the scalp or directly stimulate a strand in the way a cosmetic hair product might. It changes part of the immune environment in which that follicle is trying to grow.
The drug also has uses far beyond hair. Upadacitinib is prescribed for conditions including rheumatoid arthritis and giant cell arteritis, which makes its arrival in dermatology less strange than it first sounds. Rinvoq is also used for other immune-mediated conditions, including atopic dermatitis and ulcerative colitis.
What did the Phase 3 trials show?
Here, the numbers become useful. The Phase 3 UP-AA clinical program included two randomized trials with 1,399 adults and adolescents who had severe alopecia areata. Participants received placebo or once-daily doses of 15 mg or 30 mg.
At 24 weeks, 45.2% and 44.6% of patients taking 15 mg reached at least 80% scalp hair coverage in the two studies. With 30 mg, 55.0% and 54.3% reached the same endpoint. The placebo groups were 1.5% and 3.4%. The AA clinical trials also looked at improvements in eyebrow and eyelash hair, which can be affected in more extensive disease.
What does 80% scalp coverage mean?
The studies used the alopecia tool salt score or the Severity of Alopecia Tool (SALT). A SALT score of 20 means that 20% or less of the scalp remains without hair. It is a useful research threshold, not a guarantee about density, styling, or how a result will look in the mirror.
Some participants went further. Complete scalp hair regrowth at week 24 occurred in 13.1% to 14.1% of those taking 15 mg and 20.3% to 22.5% taking 30 mg across the two trials.
Clinical scores can make hair loss sound abstract. Dr. Levent Acar puts it simply: “When people look at a face, the density and hairline are immediately connected with youthfulness and health.” For many patients, that is why regrowth can matter beyond a number on a chart.
A hair transplant Turkey before and after gallery shows a different kind of change. Those photographs document follicles that have been moved; a drug trial follows hair returning from follicles that were already there.
A bald patch can look like an absence. Under the skin, the follicle may still be waiting. That is one of the quirks of alopecia areata, and it helps explain the interest in Rinvoq for alopecia areata.
Rinvoq is the brand name for upadacitinib, an oral JAK inhibitor already used for several immune-mediated conditions. In 2026, the European indication expanded to severe alopecia areata in adults and adolescents 12 years of age and older. The tablet is taken once a day; visible regrowth, if it comes, moves on a much slower clock.
Who might be considered for Rinvoq?
A single patch does not automatically lead to systemic treatment. In Europe, Rinvoq is approved to treat alopecia areata when it is severe in adults and adolescents from age 12.
Extent is only part of the decision. Duration, previous treatment, eyebrow or eyelash loss, infection history, and other medical conditions can all change the conversation. Smaller or more limited areas may still be managed with local approaches.
How is Rinvoq taken?
Rinvoq is an oral tablet taken once daily. The alopecia trials studied upadacitinib doses of 15 mg and 30 mg, and both produced better scalp-hair outcomes than placebo.
The larger dose had higher response rates in the trials, but dose selection is not a simple “more is better” decision. Age, other medicines, and individual risk factors still matter. Rinvoq is a prescription treatment and requires medical supervision.
What belongs in the safety conversation?
Quite a bit. Changing immune signaling throughout the body can affect more than the scalp, so the safety profile belongs alongside the regrowth data rather than underneath it.
In the Phase 3 trials, adverse events reported in more than 5% of at least one treatment group, and the side effects included acne, nasopharyngitis, raised creatine phosphokinase, and upper respiratory tract infections. No new safety signals were identified during the controlled trial period, but upadacitinib already carries important class and product warnings.
When might patients notice results?
Hair regrowth does not move at the same pace for everyone. Some people may see results earlier than others, depending on a range of factors. The main trial endpoint was measured at 24 weeks, although some responses appeared earlier. A few short hairs at week six and a fuller scalp at month six are very different checkpoints.
That is where photographs help. Taken in similar lighting, with the same parting and angle, they can show gradual change much better than memory or a daily look in the mirror.
How does Rinvoq compare with other options?
Rinvoq joins a treatment landscape that already includes other JAK inhibitors and more traditional local or systemic therapies. A systematic review of randomized JAK-inhibitor trials found better hair-regrowth outcomes with oral JAK inhibitors than placebo, while also noting the need for longer-term evidence.
Different drugs in the class are not interchangeable. Approved ages, dosing, trial populations, and safety considerations vary, so separate studies shouldn’t be treated as a simple ranking.
Surgery belongs in another lane. Someone researching Turkey hair transplant cost is usually asking about permanent hair loss where donor follicles can be moved. Active alopecia areata first needs an assessment of the autoimmune process.
FAQ about Rinvoq for alopecia areata
Is Rinvoq a steroid?
No. Upadacitinib is a JAK inhibitor, not a corticosteroid.
Can Rinvoq regrow all scalp hair?
It can happen, but not for everyone. The Phase 3 trials included patients with complete, partial, and limited responses.
How quickly can it work?
The main controlled comparison was at 24 weeks. Hair growth can begin earlier, but the practical timeline is measured in months.
Can teenagers take Rinvoq for alopecia areata?
In the European Union, the severe alopecia areata indication begins at age 12. Approval and prescribing rules may differ elsewhere.
Is treatment permanent once the hair comes back?
Not necessarily. Alopecia areata remains an immune-mediated disease, and decisions about continuing, changing or stopping treatment belong with the prescribing clinician.
Rinvoq for alopecia areata gives severe disease another systemic option. The visible problem is missing hair; underneath, the story is immune signaling, follicles that may still be viable, and enough time to see whether they respond.